Meeting
2015 ASCO Annual Meeting
Targeting c-Met overexpression for overcoming acquired resistance to EGFR TKIs in NSCLC.
Authors
Lanying Gou Jr.
Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
Lanying Gou Jr., Yi-Long Wu , Jinji Yang , Xuchao Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8091)
DOI
10.1200/jco.2015.33.15_suppl.8091
Abstract #
8091
Poster Bd #
415
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Crizotinib in advanced non-small-cell lung cancer with de novo c-Met overexpression.
First Author: An Na Li
Poster
2014 ASCO Annual Meeting
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC.
First Author: Marzia Del Re
Poster
2022 ASCO Annual Meeting
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.
First Author: Conor Ernst Steuer
Poster
2022 ASCO Annual Meeting
Real-world (rw) analysis of quantitative MET copy number (CN) as a biomarker in NSCLC.
First Author: David Chun Cheong Tsui